{"url_path":"/sec/bcyc/8-k/2026-05-21/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-21","source_url":"https://www.sec.gov/Archives/edgar/data/1761612/0001104659-26-065231-index.html","accession_number":"0001104659-26-065231","cik":"0001761612","ticker":"BCYC","issuer_name":"BICYCLE THERAPEUTICS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1761612/0001104659-26-065231-index.html","primary_entity_key":"0001761612","primary_entity_name":"BICYCLE THERAPEUTICS PLC"},"word_count":63,"has_tables":true,"body_markdown":"**Item 8.01.**\n**Other Events**\n\n \n\nOn May 21, 2026, Bicycle Therapeutics plc (the\n“Company”) issued a press release announcing initial Duravelo-2 data for metastatic urothelial cancer at the\n2026 American Society of Clinical Oncology (“ASCO”) Annual Meeting. A copy of the press release is attached as Exhibit 99.1\nto this Current Report on Form 8-K and is incorporated into this Item 8.01 by reference."}